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Abstract
Background: There are large variations in prognosis among hepatocellular carci-
noma (HCC) patients undergoing radiofrequency ablation (RFA). However, current 
staging or scoring systems hardly discriminate the outcome of HCC patients treated 
with RFA.
Methods: A total of 757 treatment‐naïve HCC patients undergoing RFA (deriva-
tion cohort) were analyzed to establish a nomogram for disease‐free survival (DFS) 
based on Cox proportional hazard regression model. Accuracy of the nomogram was 
assessed and compared with conventional staging or scoring systems. Furthermore, 
external validation was performed in an independent cohort including 208 patients 
(validation cohort).
Results: Tumor size, tumor number, alpha‐fetoprotein, prothrombin induced by vita-
min K absence‐II, lymphocyte count, albumin, and presence of ascites were adopted 
to construct the prognostic nomogram from the derivation cohort. Calibration curves 
to predict probability of DFS at 3 and 5 years after RFA showed good agreements be-
tween the nomogram and actual observations. The concordance index of the present 
nomogram was 0.759 (95% confidence interval 0.728‐0.790), which was superior to 
those of conventional staging or scoring systems (range 0.505‐0.683, all P < .001). 
These results were also reproduced in the validation cohort.
Conclusion: Our simple‐to‐use nomogram optimized for treatment‐naïve HCC pa-
tients undergoing RFA provided better prognostic performance than conventional 
staging or scoring systems.
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1 |  INTRODUCTION
Hepatocellular carcinoma (HCC) has been ranked as the sixth 
most common malignancy and the fourth most frequent cause 
of cancer‐related death in the world.1 Hepatic resection or 
liver transplantation is the preferred curative treatment mo-
dality for patients with HCC.2 However, only a minor portion 
could become eligible candidates at the time of diagnosis due 
to various reasons such as limited hepatic functional reserve, 
shortage of organ donor, high morbidities and mortalities ac-
companied by surgery, and patients’ refusal.3 Thus, various 
approaches have been developed as nonsurgical treatment op-
tions.4,5 Among these, percutaneous radiofrequency ablation 
(RFA) is recommend as a first‐line treatment in very early 
stage HCC (single tumor with a diameter <2 cm) and an al-
ternative first‐line treatment in early stage HCC (up to three 
HCC with a maximal diameter <3 cm), specifically in light 
of its lesser invasiveness and better tolerability compared to 
hepatic resection.6 Furthermore, over the several decades, 
primarily owing to the advances in RFA techniques, more 
reliable tumor control with lesser complications has been 
achieved.7 However, the high rates of postprocedural recur-
rence (either local or distant), which might be up to 70% at 
5 years, remain a major challenge for long‐term survival.8
Several staging or scoring systems had been proposed to 
predict survival and to guide treatment strategies in patients 
with HCC, so far. Nevertheless, their performances to pre-
dict the prognosis among those treated with RFA have been 
largely limited, because such systems were originally de-
signed to cover the full spectrum of HCC patients (from very 
early to far advanced stage cases), rather than “very early or 
early stage” HCC patients.9 In addition, individual‐based 
comprehensive analysis using robust clinical parameters in-
cluding classical tumor factors (eg, size or number), biomark-
ers, hepatic reserve, and other host factors is still scarce.
In this study, we aimed to establish a prognostic nomo-
gram to predict postprocedural outcomes in HCC patients 
treated with RFA as a first‐line treatment and to externally 
validate its predictive performance in an independent cohort.
2 |  MATERIALS AND METHODS
2.1 | Derivation and validation cohort
Between February 2005 and December 2014, treatment‐
naïve patients with HCC who underwent RFA as an initial 
treatment at Severance Hospital, Seoul, Republic of Korea, 
were considered eligible for the derivation cohort. Inclusion 
criteria were as follows: age  ≥  19  years old; at least one 
unidimensional lesion measurable according to modified 
Response Evaluation Criteria in Solid Tumors (mRECIST)10; 
tumor size up to 5  cm; tumor number up to 3; Eastern 
Cooperative Oncology Group performance status of 0‐2; 
platelet count  ≥  50  ×  103/µL; serum aspartate aminotrans-
ferase (AST) or alanine aminotransferase (ALT) level < 10 
times the upper limit of normal. Exclusion criteria were as 
follows: the presence of portal or hepatic vein invasion; the 
presence of extrahepatic spread; Child‐Pugh class C; any 
other uncontrolled comorbidities or malignant neoplasm; and 
a prior liver transplant. During the same period, treatment‐
naïve patients with HCC who underwent RFA as an initial 
treatment at Gangnam Severance Hospital, Seoul, Republic 
of Korea, were considered eligible for the independent vali-
dation cohort. The same inclusion and exclusion criteria were 
applied.
The study was performed in accordance with the 
Declaration of Helsinki and Good Clinical Practice and was 
approved by the institutional review boards (4‐2018‐0969). 
Informed consent for the invasive procedures was acquired 
from all patients.
2.2 | Data collection
The collected clinical data were as follows: patients’ base-
line clinical features before the primary RFA (age, gender, 
laboratory findings including alpha‐fetoprotein [AFP] and 
prothrombin induced by vitamin K absence‐II [PIVKA‐II], 
tumor etiologies, and hepatic functional reserve) and pri-
mary tumor factors such as tumor number and tumor size. 
Neutrophil‐to‐lymphocyte ratio (NLR) was calculated by 
dividing absolute neutrophil count by lymphocyte count. 
Albumin‐bilirubin (ALBI) grade was calculated based on a 
previous report.11 Furthermore, American Joint Committee 
on Cancer stage,12 Barcelona Clinic Liver Center stage,13 
Cancer of the Liver Italian Program score,14 Chinese 
University Prognostic Index,15 Okuda stage,16 Japan 
Integrated Staging (JIS) score,17 and Group d’Etude ed te 
Traitement du Carcinome Hepatocellular18 were assessed in 
each patient (Table S1).
2.3 | RFA procedure and follow‐up
The diagnosis of HCC was confirmed based on current prac-
tice guidelines of the American Association for the Study of 
Liver Diseases and the European Association for the Study of 
the Liver.4,19 Planning ultrasound was routinely performed to 
assess the feasibility and applicability for RFA. Experienced 
interventional radiologists performed the RFA procedures. 
Briefly, patients were treated percutaneously using an RFA 
device under ultrasound guidance. The tumor was ablated 
until complete ablation of the entire tumor was achieved. 
Immediately after RFA, complete ablation was confirmed 
with a dynamic CT scan. Laboratory tests including tumor 
markers (AFP, PIVKA‐II) and imaging studies (dynamic 
CT or MRI) were performed 1 month post‐RFA and every 
3 months thereafter to monitor tumor recurrence.
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2.4 | Statistical analysis
Variables are expressed as the median (interquartile range 
[IQR]), or number (%) as appropriate. Differences among 
continuous and categorical variables were examined for sta-
tistical significance with Student's t test (or Mann‐Whitney 
test, if appropriate) and chi‐squared test (or Fisher's exact 
test, if appropriate). The primary endpoint used for a model 
development was disease‐free survival (DFS), defined as the 
time between RFA and recurrence, death from any cause, or 
the last date of follow‐up. DFS was calculated using Kaplan‐
Meier analysis and compared by log‐rank test. To identify 
the factors associated with DFS in the derivation cohort, 
Cox‐regression model was used to calculate the hazard ratio 
(HR) and 95% confidence interval (CI) of each variable on 
univariate and multivariate analyses. Factors significantly as-
sociated with DFS on multivariate analysis were adopted to 
construct a nomogram and the weighted risk score of each 
variable in the model was calculated based on β‐regression 
coefficient by Cox‐regression model.
The performance of a novel prognostic model to pre-
dict the probability of DFS at 6‐60 months after RFA was 
estimated as integrated area under the curve (iAUC). For 
calibration, bootstraps with 1000 resamples were used to 
compare actual survival and predicted survival derived 
from the prognostic model at 3 and 5  years after RFA. 
Furthermore, the overall prognostic performance of the 
prognostic model was assessed using the concordance 
index (c‐index). The c‐index was compared between our 
nomogram and other conventional staging or scoring sys-
tems. For external validation, similar methods were applied 
for the independent cohort.
P <  .05 was considered statistically significant. All sta-
tistical analyses were performed using R software (version 
3.5.0., http://cran.r-proje ct.org/).
3 |  RESULTS
3.1 | Patients’ baseline characteristics and 
overall prognosis in the derivation cohort
In total, 757 patients were included in the derivation co-
hort. Baseline clinical characteristics are described in the 
Table 1. The median follow‐up duration was 39.8 months, 
the median age was 63 years, and 77.3% were male. Chronic 
hepatitis B virus (HBV) infection was the most common eti-
ology, accounting for more than 75%. The median tumor size 
was 1.8  cm (IQR 1.4‐2.4  cm). The median values of AFP 
and PIVKA‐II were 7.9  ng/mL (IQR 3.2‐44.1  ng/mL) and 
29  mAU/mL (IQR 19‐55  mAU/mL), respectively. During 
follow‐up, 400 patients (52.8%) experienced HCC recurrence 
after RFA in the derivation cohort. The DFS rates at 3 and 
5 years were 41.4% and 31.5%, respectively.
3.2 | Development of the 
prognostic nomogram and its performance
Fifteen variables were assessed on univariate analysis to 
identify significant factors associated with DFS in the deriva-
tion cohort. Subsequently, variables with P < .05 on univari-
ate analysis including etiology, tumor size, tumor number, 
AFP, PIVKA‐II, neutrophil count, lymphocyte count, ane-
mia, platelet count, bilirubin, albumin, ascites, AST, ALT, 
and ALP (alkaline phosphatase) levels were entered into a 
multivariate Cox‐regression model. Finally, seven essential 
variables including tumor size, tumor number, AFP level, 
PIVKA‐II level, lymphocyte count, albumin level, and pres-
ence of ascites were identified as prognostic factors with 
statistical significance (Table 2). Based on β‐regression co-
efficients calculated from the final Cox‐regression model, a 
weighted risk score with a rounded form to the integer value 
was allocated to each variable to construct a prognostic nom-
ogram (Table 3). The prognostic nomogram was expressed as 
the total sum of each risk score (Figure 1).
The proposed prognostic nomogram showed a fairly good 
discrimination capability to predict DFS at 6‐60  months 
after RFA, with iAUC of 0.780 (Figure 2A). Furthermore, 
the actual DFS was in good agreement with the predicted 
DFS at 3  years (Figure 2B) and 5  years (Figure 2C). The 
overall c‐index of the prognostic model was 0.759 (95% CI 
0.728‐0.790) and was higher than those of the conventional 
staging or scoring systems (Table S2).
Patients were stratified into three groups (low‐, interme-
diate‐, and high‐risk groups) according to the tertile of the 
total sum of allocated scores from the prognostic nomogram; 
the median DFS rates of low‐, intermediate‐, and high‐
risk groups were 106.3, 33.6, and 9.3 months, respectively 
(P < .001 by log‐rank test, Figure 3A).
3.3 | Recruitment of the independent 
validation cohort and external validation of the 
prognostic nomogram
A total of 208 patients were included in the validation co-
hort. As shown in Table 1 and Table S1, patients’ baseline 
characteristics in the validation cohort were well balanced in 
comparison with the derivation cohort (all P > .05). During 
the median follow‐up of 42.0 months, 112 patients (53.8%) 
experienced HCC recurrence. DFS at 3 and 5  years were 
41.7% and 31.5%, respectively. There was no significant dif-
ference in DFS between the derivation and validation cohorts 
(P = .711 by log‐rank test).
The discriminative ability of the nomogram among the 
validation cohort was similar in terms of iAUC metrics to pre-
dict DFS at 6‐60 months after RFA (Figure 4A), and agree-
ment of the predicted and actual DFS at 3 years (Figure 4B) 
and 5 years (Figure 4C). The overall c‐index of the prognostic 
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nomogram was 0.748 (95% CI 0.694‐0.803), which was also 
higher than those of the conventional staging or scoring sys-
tems (Table S3). The median DFS of low‐, intermediate‐, and 
high‐risk groups were 112.2, 34.8, and 11.6 months, respec-
tively (P < .001 by log‐rank test, Figure 3B).
3.4 | Prognostic nomogram incorporating 
NLR and ALBI grade
We also investigated whether NLR and ALBI grade rather than 
simple lymphocyte count or albumin level have discriminative 
ability in predicting DFS. There was no statistical differences 
in NLR and ALBI grade between the validation cohort and 
derivation cohort (Table S4). On univariate analysis, NLR 
and ALBI grade were associated with DFS in the derivation 
cohort, which was entered into a multivariate Cox‐regression 
model (Table S5). On multivariate analysis, tumor size, tumor 
number, AFP level, PIVKA‐II level, presence of ascites, NLR, 
and ALBI grade were identified as prognostic factors with sta-
tistical significance (Table S6). The prognostic nomogram was 
generated based on the total sum of the risk scores (Figure S1). 
The nomogram showed a good discrimination capability to 
predict DFS at 6‐60 months after RFA, with c‐index of 0.755 
for the derivation cohort and 0.746 for the validation cohort, 
respectively. When patients were stratified into three groups 
based on the sum of the risk scores, DFS was clearly separated 
both on the derivation and validation cohorts (Figure S2).
T A B L E  1  Patient characteristics of the derivation and validation 
cohorts
Variables
Derivation co-
hort (n = 757)
Validation 
cohort 
(n = 208) P value
Age     .102
Median (IQR), 
years
63 (55‐69) 60 (54‐68)  
Sex     .206
Male 585 (77.3%) 152 (73.1%)  
Female 172 (22.7%) 56 (26.9%)  
Etiology     .928
HBV 560 (74.0%) 150 (72.1%)  
HCV 123 (16.2%) 36 (17.3%)  
HBV, HCV 9 (1.2%) 2 (1.0%)  
NBNC 65 (8.6%) 20 (9.6%)  
Tumor size     .749
<2 cm 407 (53.8%) 116 (55.8%)  
2‐3 cm 260 (34.3%) 71 (34.1%)  
≥3 cm 90 (11.9%) 21 (10.1%)  
Tumor numbers     .945
1 644 (85.1%) 175 (84.1%)  
2 82 (10.8%) 24 (11.5%)  
3 31 (4.1%) 9 (4.3%)  
AFP     .218
<20 ng/mL 490 (64.7%) 125 (60.1%)  
≥20 ng/mL 267 (35.3%) 83 (39.9%)  
PIVKA‐II     .381
<40 mAU/mL 505 (66.7%) 132 (63.5%)  
≥40 mAU/mL 252 (33.3%) 76 (36.5%)  
Neutrophil     .377
<4000/µL 227 (30.0%) 69 (33.2%)  
≥4000/µL 139 (70.0%) 139 (66.8%)  
Lymphocyte     .163
<2000/µL 484 (63.9%) 122 (58.7%)  
≥2000/µL 273 (36.1%) 86 (41.3%)  
Anemia     .097
Presence 217 (28.7%) 72 (34.6%)  
Absence 540 (71.3%) 136 (65.4%)  
Platelet     .693
<150 × 103/
µL
567 (74.9%) 153 (73.6%)  
≥150 × 103/
µL
190 (25.1%) 55 (26.4%)  
Bilirubin     .814
<2 mg/dL 720 (95.1%) 197 (94.7%)  
≥2 mg/dL 37 (4.9%) 11 (5.3%)  
(Continues)
Variables
Derivation co-
hort (n = 757)
Validation 
cohort 
(n = 208) P value
Albumin     .839
≤3.5 g/dL 231 (30.5%) 65 (31.2%)  
>3.5 g/dL 526 (69.5%) 143 (68.8%)  
Ascites     .959
Presence 81 (10.7%) 22 (10.6%)  
Absence 676 (89.3%) 186 (89.4%)  
AST     .424
<40 IU/L 373 (49.3%) 109 (52.4%)  
≥40 IU/L 384 (50.7%) 99 (47.6%)  
ALT     .780
<40 IU/L 625 (82.6%) 170 (81.7%)  
≥40 IU/L 132 (17.4%) 38 (18.3%)  
ALP     .841
<143 IU/L 703 (92.9%) 194 (93.3%)  
≥143 IU/L 54 (7.1%) 14 (6.7%)  
Abbreviations: AFP, alpha‐fetoprotein; ALP, alkaline phosphatase; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B 
virus; HCV, hepatitis C virus; IQR, interquartile range; NBNC, non‐B, non‐C; 
PIVKA‐II, prothrombin induced by vitamin K absence‐II.
T A B L E  1  (Continued)
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T A B L E  2  Factors associated with disease‐free survival in the derivation cohort
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value Adjusted HR (95% CI) P value
Age   .229    
<65 years Ref      
≥65 years 1.129 (0.927‐1.375)      
Sex   .239    
Male 1.151 (0.911‐1.454)      
Female Ref      
Etiology   .008   .307
HCV 1.338 (1.090‐1.768)   1.144 (0.883‐1.482)  
Non‐HCV Ref   Ref  
Tumor size   <.001   <.001
<2 cm Ref   Ref  
2‐3 cm 2.061 (1.654‐2.569)   1.868 (1.488‐2.345)  
≥3 cm 6.562 (4.958‐8.686)   5.100 (3.780‐6.881)  
Tumor numbers   <.001   <.001
1 Ref   Ref  
2 2.291 (1.705‐3.077)   1.581 (1.156‐2.163)  
3 4.887 (3.337‐7.158)   4.007 (2.696‐5.957)  
AFP   <.001   .001
<20 ng/mL Ref   Ref  
≥20 ng/mL 1.595 (1.307‐1.946)   1.443 (1.172‐1.777)  
PIVKA‐II   <.001   001
<40 mAU/mL Ref   Ref  
≥40 mAU/mL 1.980 (1.625‐2.412)   1.451 (1.174‐1.793)  
Neutrophil   <.001   .419
<4000/µL 1.471 (1.198‐1.807)   1.099 (0.874‐1.383)  
≥4000/µL Ref   Ref  
Lymphocyte   <.001   .026
<2000/µL 1.537 (1.242‐1.902)   1.332 (1.034‐1.714)  
≥2000/µL Ref   Ref  
Anemia   <.001   .565
Presence 1.830 (1.493‐2.242)   1.074 (0.842‐1.369)  
Absence Ref   Ref  
Platelet   .009   .604
<150 × 103/µL 1.366 (1.080‐1.728)   0.928 (0.698‐1.232)  
≥150 × 103/µL Ref   Ref  
Bilirubin   .001   .859
<2 mg/dL Ref   Ref  
≥2 mg/dL 1.891 (1.287‐2.778)   0.963 (0.632‐1.465)  
Albumin   <.001   .008
≤3.5 g/dL 2.413 (1.976‐2.946)   1.408 (1.092‐1.817)  
>3.5 g/dL Ref   Ref  
Ascites   <.001   .001
Presence 1.740 (1.317‐2.300)   1.636 (1.209‐2.213)  
(Continues)
5028 |   GON KIM et al
4 |  DISCUSSION
Nomograms are widely used as prognostic tools in routine 
clinical practice since they have the ability to fulfill desire 
toward personalized medicine through integrating diverse 
prognostic and determinant variables.20 In the current study, 
based on the previous experience that large variations exist 
in clinical outcomes among patients with HCC undergo-
ing RFA as first‐line treatment,21 we aimed to develop and 
validate a novel prognostic nomogram optimized for such 
patients through large patient cohorts. As a matter of fact, 
current staging or scoring systems have hardly discriminated 
the individual patient’s prognosis because they did not fully 
appreciate the heterogeneity of HCC patients treated with 
RFA.22 By a novel nomogram using the tumor characteris-
tics, hepatic functional reserve, and host's immunological 
factor, accurate stratification of HCC patients treated with 
RFA into distinct prognostic subgroups might be available, 
providing a better discriminatory ability compared to other 
staging or scoring systems.
Our study has several strengths. First, even though there 
have been several studies concerning the prognostic model 
for HCC patients treated with RFA to overcome the disad-
vantages of conventional staging or scoring systems,23-25 
they were primarily limited by inadequate external valida-
tion, which is a critical component to confirm the prognostic 
system. So, we tried to recruit an independent cohort during 
the same study period to support the clinical relevance of 
our proposed nomogram. In addition, the large sample size 
of more than 700 patients in the derivation cohort may have 
further improved the statistical power, compared to the pre-
vious study.22 Second, the easy‐to‐use graphical tool consists 
of variables routinely evaluated in clinics such as tumor size, 
tumor number, AFP level, PIVKA‐II level, lymphocyte count, 
albumin level, and presence of ascites. Therefore, additional 
costly tests may not be necessary. Notably, we suggest that 
PIVKA‐II level is independently associated with prognosis. 
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value Adjusted HR (95% CI) P value
Absence Ref   Ref  
AST   <.001   .411
<40 IU/L Ref   Ref  
≥40 IU/L 1.742 (1.425‐2.130)   1.107 (0.869‐1.410)  
ALT   .013   .169
<40 IU/L Ref   Ref  
≥40 IU/L 1.359 (1.066‐1.733)   1.213 (0.921‐1.597)  
ALP   <.001   .399
<143 IU/L Ref   Ref  
≥143 IU/L 2.225 (1.626‐3.046)   1.162 (0.820‐1.647)  
Abbreviations: AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CI, confidence interval; HR, 
hazard ratio; HCV, hepatitis C virus; PIVKA‐II, prothrombin induced by vitamin K absence‐II; Ref, reference.
T A B L E  2  (Continued)
T A B L E  3  β‐coefficient and risk score from multivariate Cox‐
regression model in the derivation cohort
Variables β‐coefficient P value Risk score
Tumor size   <.001  
<2 cm Ref   0
2‐3 cm 0.635   50
≥3 cm 1.646   100
Tumor numbers   <.001  
1 Ref   0
2 0.517   42
3 1.395   85
AFP   <.001  
<20 ng/mL Ref   0
≥20 ng/mL 0.402   9
PIVKA‐II   <.001  
<40 mAU/mL Ref   0
≥40 mAU/mL 0.380   23
Lymphocyte   .010  
<2000/µL 0.287   0
≥2000/µL Ref   2
Albumin   <.001  
≤3.5 g/dL 0.444   0
>3.5 g/dL Ref   39
Ascites   .001  
Presence 0.469   0
Absence Ref   15
Abbreviations: AFP, alpha‐fetoprotein; PIVKA‐II, prothrombin induced by 
vitamin K absence‐II; Ref, reference.
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To date, the prognostic role of PIVKA‐II, especially for 
patients treated with RFA, has remained elusive.4,19,26,27 
However, our study provides clear evidence on the value of 
measuring PIVKA‐II level at baseline for risk stratification. 
Given that its weight may be larger than that of AFP, but less 
than that of tumor size or number, PIVKA‐II level might be 
used as an ancillary method to complement conventional 
tumor factors for delicate prognostification. Furthermore, it 
is noteworthy that lymphopenia has been identified as a prog-
nostic factor in HCC. To date, in other solid tumors including 
breast, renal, colorectal, prostate, and bladder cancer, lymph-
openia has been proposed as a poor prognostic factor.28 
As lymphocytes are a crucial part of antitumor immunity, 
lymphopenia can be a surrogate marker of tumor‐induced 
immune suppression. To our knowledge, this is the first study 
to address the role of lymphopenia in HCC patients treated 
with RFA. In a similar context, the benefit of adjuvant autol-
ogous T‐lymphocyte‐based immunotherapy to improve post‐
RFA prognosis had already been proven through a phase III 
trial,29 and more recently, a phase III clinical trial to assess 
F I G U R E  1  Nomogram for disease‐
free survival in patients with hepatocellular 
carcinoma treated with radiofrequency 
ablation. AFP, alpha‐fetoprotein; PIVKA, 
prothrombin induced by vitamin K absence‐
II.
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the beneficial effect of adjuvant immune checkpoint inhibitor 
which can enhance the host's T‐cell activity (NCT03383458) 
is still ongoing. Another hypothesis explaining the prognos-
tic role of lymphopenia might be suggested. In the setting of 
underlying liver cirrhosis and portal hypertension, increased 
neutrophil and monocyte counts and decreased lymphocyte 
count might reflect the severity of liver disease,30,31 which 
is closely associated with de novo HCC in the background 
liver.32 Intriguingly, NLR was also found to have prognos-
tic power similar to that observed in other studies.33-35 Other 
variables of our nomogram, which are tumor size, tumor 
number, AFP, hypoalbuminemia, and ascites, also have suf-
ficient scientific rationale in determining patients’ prognosis, 
consistent with the previous literature.36-38 We also validated 
that ALBI grade can independently discriminate patients’ 
prognosis in the setting of RFA.
When patients were stratified into low‐, intermediate‐, 
and high‐risk groups, the median DFS rates were 106.3, 
33.6, and 9.3  months, respectively. Hence, our proposed 
nomogram can be utilized in routine clinical practice in 
establishing optimal surveillance protocols, guiding treat-
ment strategies, identifying potential candidates for effec-
tive adjuvant therapy, or designing future clinical trials. 
For example, local ablation might be preferred to hepatic 
resection in terms of its less invasiveness for the low‐risk 
group, whereas hepatic resection might be preferred in 
terms of better tumor control for intermediate‐ or high‐risk 
groups. Furthermore, in order to maximize the therapeutic 
benefit of costly adjuvant immunotherapy and to optimize 
the number of patients needed to be treated, high‐risk group 
might be considered reasonable candidates for such adjuvant 
immunotherapy.
Although our study attempted to overcome the shortcom-
ings of previous studies, several unresolved limitations exist. 
First, this is an observational study which includes single‐
ethnic population in a HBV‐endemic geographic area, which 
is somewhat subject to selection bias. However, to confirm 
the reliability of our study with robust evidence, we tried to 
conduct external validation in an independent cohort where 
the variables were well balanced in comparison to those of 
F I G U R E  3  Kaplan‐Meier curves 
according to the risk stratification by the 
prognostic nomogram among the derivation 
(A) and validation (B) cohorts
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the derivation cohort. Furthermore, since there has been no 
evidence of a relationship between the ethnicity or the etiol-
ogy and the prognosis of HCC patients treated with RFA,25 
this nomogram may be widely applicable. Furthermore, this 
cohort did not include patients treated with the newer ablation 
methods such as microwave ablation or irreversible electro-
phoration.8,39,40 Since such methods to treat early‐stage HCC 
have not yet been popular in the Republic of Korea, further 
studies are required to keep pace with the latest up‐to‐date 
knowledge.
In conclusion, a simple individualized nomogram opti-
mized for treatment‐naïve HCC patients undergoing RFA as 
a first‐line treatment allowed more delicate prognostification 
in terms of HCC recurrence, with the appropriate verification 
in an independent cohort. This novel prognostic calculator 
can serve as a useful instrument for not only guiding surveil-
lance schedules and treatment strategies but also designing 
future prospective clinical trials.
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